Wunderlich Securities Comments on Edwards Lifesciences

Wunderlich Securities provided color on Edwards Lifesciences

in a research report published today. Wunderlich Securities has a $75 price target and Hold rating on Edwards Lifesciences. In the report, Wunderlich Securities states, "We had assumed the transapical approach would eventually gain FDA approval, but the data presented yesterday helps remove uncertainty from the situation. We believe the significantly lower stroke rate is especially favorable, as we thought that would represent the biggest hurdle for the company with respect to an FDA panel meeting. We believe the CAP patients benefited from a physician “learning curve” with SAPIEN, and the adoption of clinical “best practices” for high-risk surgical patients." Shares of Edwards Lifesciences were trading at $83.03 at the time of posting, up 6.08% from Monday's market close.